Imaging in Parkinson's Disease

International Review of Neurobiology

Volumn 132, Issue , 2017, Pages 233-274

  Politis, Marios ^a   Pagano, Gennaro ^a   Niccolini, Flavia ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

De novo PD; DLB; MRI; Parkinson's disease; PDD; PET; SPECT

Indexed keywords

6 FLUORODOPA F 18; ACETYLCHOLINESTERASE; ADENOSINE A2A RECEPTOR; ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; APOMORPHINE; CANNABINOID 1 RECEPTOR; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE TRANSPORTER; FLORTAUCIPIR F 18; GLUTAMIC ACID; LEVODOPA; MUSCARINIC RECEPTOR; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE C 11; NEUROMELANIN; NICOTINIC RECEPTOR; OPIATE RECEPTOR; PHOSPHATASE; PIMAVANSERIN; PITTSBURGH COMPOUND B; PLACEBO; RACLOPRIDE C 11; SEROTONIN TRANSPORTER; SIGMA 1 OPIATE RECEPTOR; VERDIPERSTAT;

AMYLOID PLAQUE; BRAIN ATROPHY; CHOLINERGIC SYSTEM; CORTICAL THICKNESS (BRAIN); DELUSION; DEMENTIA; DEPRESSION; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; DIFFUSION WEIGHTED IMAGING; DISEASE SEVERITY; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; FETAL TISSUE TRANSPLANTATION; FRACTIONAL ANISOTROPY; FUNCTIONAL CONNECTIVITY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HALLUCINATION; HUMAN; IMPULSE CONTROL DISORDER; LOCUS CERULEUS; MOLECULAR IMAGING; NERVOUS SYSTEM INFLAMMATION; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN MISFOLDING; PSYCHOSIS; SEROTONINERGIC SYSTEM; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY; SUBSTANTIA NIGRA PARS COMPACTA; SUSCEPTIBILITY WEIGHTED IMAGING; TREMOR; UNIFIED PARKINSON DISEASE RATING SCALE; VENTRAL MESENCEPHALON; DIAGNOSTIC IMAGING; PROCEDURES;

HUMANS; NEUROIMAGING; PARKINSON DISEASE;

EID: 85016487197     PISSN: 00747742     EISSN: 21625514     Source Type: Book Series    
DOI: 10.1016/bs.irn.2017.02.015     Document Type: Chapter

References (289)

1. Agosta, F., Canu, E., Stefanova, E., Sarro, L., Tomic, A., Spica, V., et al. Mild cognitive impairment in Parkinson's disease is associated with a distributed pattern of brain white matter damage. Human Brain Mapping 35 (2014), 1921–1929.
2. Ahmad, R., Bourgeois, S., Postnov, A., Schmidt, M.E., Bormans, G., Van Laere, K., et al. PET imaging shows loss of striatal PDE10A in patients with Huntington disease. Neurology 82:3 (2014), 279–281.
3. Ahmed, I., Bose, S., Pavese, N., Ramlackhansingh, A., Turkheimer, F., Hotton, G., et al. Glutamate NMDA receptor dysregulation in Parkinson's disease with dyskinesias. Brain 134 (2011), 979–986.
4. Anders, S., Sack, B., Pohl, A., Münte, T., Pramstaller, P., Klein, C., et al. Compensatory premotor activity during affective face processing in subclinical carriers of a single mutant Parkin allele. Brain 135 (2012), 1128–1140.
5. Antonini, A., Schwarz, J., Oertel, W.H., Pogarell, O., Leenders, K.L., Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: A study with positron emission tomography and [11C]raclopride. Movement Disorders 12:1 (1997), 33–38.
6. Apostolova, L.G., Beyer, M., Green, A.E., Hwang, K.S., Morra, J.H., Chou, Y.Y., et al. Hippocampal, caudate, and ventricular changes in Parkinson's disease with and without dementia. Movement Disorders 25 (2010), 687–695.
7. Asahina, M., Shinotoh, H., Hirayama, K., Suhara, T., Shishido, F., Inoue, O., et al. Hypersensitivity of cortical muscarinic receptors in Parkinson's disease demonstrated by PET. Acta Neurologica Scandinavica 91:6 (1995), 437–443.
8. Asahina, M., Suhara, T., Shinotoh, H., Inoue, O., Suzuki, K., Hattori, T., Brain muscarinic receptors in progressive supranuclear palsy and Parkinson's disease: A positron emission tomographic study. Journal of Neurology, Neurosurgery, and Psychiatry 65:2 (1998), 155–163.
9. Ballanger, B., Strafella, A.P., van Eimeren, T., Zurowski, M., Rusjan, P.M., Houle, S., et al. Serotonin 2A receptors and visual hallucinations in Parkinson disease. Archives of Neurology 67:4 (2010), 416–421.
10. Banati, R.B., Visualising microglial activation in vivo. Glia 40 (2002), 206–217.
11. Banati, R.B., Goerres, G.W., Myers, R., Gunn, R.N., Turkheimer, F.E., Kreutzberg, G.W., et al. [11C](R)-PK11195 positron emission tomography imaging of activated microglia in vivo in Rasmussen's encephalitis. Neurology 53 (1999), 2199–2203.
12. Banati, R.B., Newcombe, J., Gunn, R.N., Cagnin, A., Turkheimer, F., Heppner, F., et al. The peripheral benzodiazepine binding site in the brain in multiple sclerosis: Quantitative in vivo imaging of microglia as a measure of disease activity. Brain 123 (2000), 2321–2337.
13. Bartus, R.T., Dean, R.L. 3rd., Beer, B., Lippa, A.S., The cholinergic hypothesis of geriatric memory dysfunction. Science (New York, NY) 217 (1982), 408–414.
14. Bartzokis, G., Cummings, J.L., Markham, C.H., Marmarelis, P.Z., Treciokas, L.J., Tishler, T.A., et al. MRI evaluation of brain iron in earlier- and later-onset Parkinson's disease and normal subjects. Magnetic Resonance Imaging 17 (1999), 213–222.
15. Bazelon, M., Fenichel, G.M., Randall, J., Studies on neuromelanin. I. A melanin system in the human adult brainstem. Neurology 17:5 (1967), 512–519.
16. Beyer, M.K., Larsen, J.P., Aarsland, D., Gray matter atrophy in Parkinson disease with dementia and dementia with Lewy bodies. Neurology 69 (2007), 747–754.
17. Biundo, R., Weis, L., Facchini, S., Formento-Dojot, P., Vallelunga, A., Pilleri, M., et al. Patterns of cortical thickness associated with impulse control disorders in Parkinson's disease. Movement Disorders 30:5 (2015), 688–695.
18. Blain, C.R., Barker, G.J., Jarosz, J.M., Coyle, N.A., Landau, S., Brown, R.G., et al. Measuring brain stem and cerebellar damage in parkinsonian syndromes using diffusion tensor MRI. Neurology 67 (2006), 2199–2205.
19. Blazejewska, A.I., Schwarz, S.T., Pitiot, A., Stephenson, M.C., Lowe, J., Bajaj, N., et al. Visualization of nigrosome 1 and its loss in PD: Pathoanatomical correlation and in vivo 7T MRI. Neurology 81 (2013), 534–540.
20. Bohnen, N.I., Frey, K.A., Studenski, S., Kotagal, V., Koeppe, R.A., Constantine, G.M., et al. Extra-nigral pathological conditions are common in Parkinson's disease with freezing of gait: An in vivo positron emission tomography study. Movement Disorders 29:9 (2014), 1118–1124.
21. Bohnen, N.I., Frey, K.A., Studenski, S., Kotagal, V., Koeppe, R.A., Scott, P.J., et al. Gait speed in Parkinson disease correlates with cholinergic degeneration. Neurology 81:18 (2013), 1611–1616.
22. Bohnen, N.I., Kaufer, D.I., Hendrickson, R., Ivanco, L.S., Lopresti, B.J., Constantine, G.M., et al. Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia. Journal of Neurology 253 (2006), 242–247.
23. Bohnen, N.I., Müller, M.L., Koeppe, R.A., Studenski, S.A., Kilbourn, M.A., Frey, K.A., et al. History of falls in Parkinson disease is associated with reduced cholinergic activity. Neurology 73:20 (2009), 1670–1676.
24. Bohnen, N.I., Müller, M.L., Kotagal, V., Koeppe, R.A., Kilbourn, M.R., Gilman, S., et al. Heterogeneity of cholinergic denervation in Parkinson's disease without dementia. Journal of Cerebral Blood Flow and Metabolism 32:8 (2012), 1609–1617.
25. Boileau, I., Guttman, M., Rusjan, P., Adams, J.R., Houle, S., Tong, J., et al. Decreased binding of the D3 dopamine receptor-preferring ligand [11C]-PHNO in drug-naive Parkinson's disease. Brain 132:Pt. 5 (2009), 1366–1375.
26. Boileau, I., Warsh, J.J., Guttman, M., Saint-Cyr, J.A., McCluskey, T., Rusjan, P., et al. Elevated serotonin transporter binding in depressed patients with Parkinson's disease: A preliminary PET study with [11C]DASB. Movement Disorders 23 (2008), 1776–1780.
27. Booth, R.G., Baldessarini, R.J., (+)-6,7-Benzomorphan sigma ligands stimulate dopamine synthesis in rat corpus striatum tissue. Brain Research 557 (1991), 349–352.
28. Boucetta, S., Salimi, A., Dadar, M., Jones, B.E., Collins, D.L., Dang-Vu, T.T., Structural brain alterations associated with rapid eye movement sleep behavior disorder in Parkinson's disease. Scientific Reports, 6, 2016, 26782.
29. Breier, A., Su, T.P., Saunders, R., Carson, R.E., Kolachana, B.S., de Bartolomeis, A., et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method. Proceedings of the National Academy of Sciences of the United States of America 94:6 (1997), 2569–2574.
30. Brooks, D.J., Frey, K.A., Marek, K.L., Oakes, D., Paty, D., Prentice, R., et al. Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease. Experimental Neurology 184 (2003), S68–S79.
31. Brooks, D.J., Ibanez, V., Saule, G.V., Playford, E.D., Quinn, N., Mathias, C.J., et al. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography. Annals of Neurology 31 (1992), 184–192.
32. Brooks, D.J., Ibanez, V., Sawle, G.V., Quinn, N., Lees, A.J., Mathias, C.J., et al. Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiplesystem atrophy and progressive supranuclear palsy. Annals of Neurology 28 (1990), 547–555.
33. Brooks, D.J., Pavese, N., Imaging biomarkers in Parkinson's disease. Progress in Neurobiology 95:4 (2011), 614–628.
34. Bunzeck, N., Singh-Curry, V., Eckart, C., Weiskopf, N., Perry, R.J., Bain, P.G., et al. Motor phenotype and magnetic resonance measures of basal ganglia iron levels in Parkinson's disease. Parkinsonism & Related Disorders 19 (2013), 1136–1142.
35. Burciu, R.G., Ofori, E., Shukla, P., Planetta, P.J., Snyder, A.F., Li, H., et al. Distinct patterns of brain activity in progressive supranuclear palsy and Parkinson's disease. Movement Disorders 30:9 (2015), 1248–1258.
36. Burke, J.F., Albin, R.L., Koeppe, R.A., Giordani, B., Kilbourn, M.R., Gilman, S., et al. Assessment of mild dementia with amyloid and dopamine terminal positron emission tomography. Brain 134 (2011), 1647–1657.
37. 11C]diprenoiphine PET study. Brain 118 (1995), 951–958.
38. Burton, E.J., McKeith, I.G., Burn, D.J., O'Brien, J.T., Brain atrophy rates in Parkinson's disease with and without dementia using serial magnetic resonance imaging. Movement Disorders 20 (2005), 1571–1576.
39. Burton, E.J., McKeith, I.G., Burn, D.J., Williams, E.D., O'Brien, J.T., Cerebral atrophy in Parkinson's disease with and without dementia: A comparison with Alzheimer's disease, dementia with Lewy bodies and controls. Brain 127 (2004), 791–800.
40. Camicioli, R., Moore, M.M., Kinney, A., Corbridge, E., Glassberg, K., Kaye, J.A., Parkinson's disease is associated with hippocampal atrophy. Movement Disorders 18 (2003), 784–790.
41. Carriere, N., Besson, P., Dujardin, K., Duhamel, A., Defebvre, L., Delmaire, C., et al. Apathy in Parkinson's disease is associated with nucleus accumbens atrophy: A magnetic resonance imaging shape analysis. Movement Disorders 29 (2014), 897–903.
42. Catafau, A.M., Searle, G.E., Bullich, S., Gunn, R.N., Rabiner, E.A., Herance, R., et al. Imaging cortical dopamine D1 receptors using [11C]NNC112 and ketanserin blockade of the 5-HT 2A receptors. Journal of Cerebral Blood Flow and Metabolism 30:5 (2010), 985–993.
43. Cerasa, A., Donzuso, G., Morelli, M., Mangone, G., Salsone, M., Passamonti, L., et al. The motor inhibition system in Parkinson's disease with levodopa-induced dyskinesias. Movement Disorders 30 (2015), 1912–1920.
44. Cerasa, A., Morelli, M., Augimeri, A., Salsone, M., Novellino, F., Gioia, M.C., et al. Prefrontal thickening in PD with levodopa-induced dyskinesias: New evidence from cortical thickness measurement. Parkinsonism & Related Disorders 19:1 (2013), 123–125.
45. Cerasa, A., Salsone, M., Morelli, M., Pugliese, P., Arabia, G., Gioia, C.M., et al. Age at onset influences neurodegenerative processes underlying PD with levodopa-induced dyskinesias. Parkinsonism & Related Disorders 19:10 (2013), 883–888.
46. Chaki, S., Okuyama, S., Ogawa, S., Tomisawa, K., Regulation of NMDA-induced [3H]dopamine release from rat hippocampal slices through sigma-1 binding sites. Neurochemistry International 33 (1998), 29–34.
47. Chan, L.-L., Rumpel, H., Yap, K., Lee, E., Loo, H.-V., Ho, G.-L., et al. Case control study of diffusion tensor imaging in Parkinson's disease. Journal of Neurology, Neurosurgery, and Psychiatry 78 (2007), 1383–1386.
48. Chauveau, F., Boutin, H., Van Camp, N., Dollé, F., Tavitian, B., Nuclear imaging of neuroinflammation: A comprehensive review of [11C]PK11195 challengers. European Journal of Nuclear Medicine and Molecular Imaging 35 (2008), 2304–2319.
49. Claassen, D.O., Lowe, V.J., Peller, P.J., Petersen, R.C., Josephs, K.A., Amyloid and glucose imaging in dementia with Lewy bodies and multiple systems atrophy. Parkinsonism & Related Disorders 17 (2011), 160–165.
50. Colloby, S.J., Williams, E.D., Burn, D.J., Lloyd, J.J., McKeith, I.G., O'Brien, J.T., Progression of dopaminergic degeneration in dementia with Lewy bodies and Parkinson's disease with and without dementia assessed using 123I-FP-CIT SPECT. European Journal of Nuclear Medicine and Molecular Imaging 32:10 (2005), 1176–1185.
51. Compta, Y., Pereira, J.B., Ríos, J., Ibarretxe-Bilbao, N., Junque, C., Bargallo, N., et al. Combined dementia-risk biomarkers in Parkinson's disease: A prospective longitudinal study. Parkinsonism & Related Disorders 19 (2013), 717–724.
52. Coskran, T.M., Morton, D., Menniti, F.S., Adamowicz, W.O., Kleiman, R.J., Ryan, A.M., et al. Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian species. The Journal of Histochemistry and Cytochemistry 54 (2006), 1205–1213.
53. Cropley, V.L., Fujita, M., Bara-Jimenez, W., Brown, A.K., Zhang, X.Y., Sangare, J., et al. Pre- and post-synaptic dopamine imaging and its relation with frontostriatal cognitive function in Parkinson disease: PET studies with [11C]NNC 112 and [18F]FDOPA. Psychiatry Research 163:2 (2008), 171–182.
54. Cuberas-Borrós, G., Lorenzo-Bosquet, C., Aguadé-Bruix, S., Hernández-Vara, J., Pifarré-Montaner, P., Miquel, F., et al. Quantitative evaluation of striatal I-123-FP-CIT uptake in essential tremor and parkinsonism. Clinical Nuclear Medicine 36:11 (2011), 991–996.
55. Cummings, J., Isaacson, S., Mills, R., Williams, H., Chi-burris, K., Corbett, A., et al. Pimavanserin for patients with Parkinson's disease psychosis: A randomised, placebo-controlled phase 3 trial. The Lancet 383 (2014), 533–540.
56. Damier, P., Hirsch, E.C., Agid, Y., Graybiel, A.M., The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28 K) immunohistochemistry. Brain: A Journal of Neurology 122:Pt. 8 (1999), 1421–1436.
57. de la Fuente-Fernandez, R., Lim, A.S., Sossi, V., Holden, J.E., Calne, D.B., Ruth, T.J., et al. Apomorphine-induced changes in synaptic dopamine levels: Positron emission tomography evidence for presynaptic inhibition. Journal of Cerebral Blood Flow and Metabolism 21 (2001), 1151–1159.
58. de la Fuente-Fernandez, R., Lu, J.Q., Sossi, V., Jivan, S., Schulzer, M., Holden, J.E., et al. Biochemical variations in the synaptic levels of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. Annals of Neurology 49 (2001), 298–303.
59. de la Fuente-Fernandez, R., Phillips, A.G., Zamburlini, M., Sossi, V., Calne, D.B., Ruth, T.J., et al. Dopamine release in human ventral striatum and expectation of reward. Behavioural Brain Research 136:2 (2002), 359–363.
60. de la Fuente-Fernandez, R., Ruth, T.J., Sossi, V., Schulzer, M., Calne, D.B., Stoessl, A.J., Expectation and dopamine release: Mechanisms of the placebo effect in Parkinson's disease. Science 293 (2001), 1164–1166.
61. de la Fuente-Fernández, R., Schulzer, M., Kuramoto, L., Cragg, J., Ramachandiran, N., Au, W.L., et al. Age-specific progression of nigrostriatal dysfunction in Parkinson's disease. Annals of Neurology 69 (2011), 803–810.
62. de la Fuente-Fernandez, R., Sossi, V., Huang, Z., Furtado, S., Lu, Q.R., Calne, D.B., et al. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: Implications for dyskinesias. Brain 127 (2004), 2747–2754.
63. 11C]raclopride PET study. Movement Disorders 14:6 (1999), 1025–1030.
64. Diaz-Corrales, F.J., Sanz-Viedma, S., Garcia-Solis, D., Escobar-Delgado, T., Mir, P., Clinical features and I123-FP-CIT SPECT imaging in drug-induced parkinsonism and Parkinson's disease. European Journal of Nuclear Medicine and Molecular Imaging 37:3 (2010), 556–564.
65. Diggle, C.P., Sukoff Rizzo, S.J., Popiolek, M., Hinttala, R., Schülke, J.P., Kurian, M.A., et al. Biallelic mutations in PDE10A lead to loss of striatal PDE10A and a hyperkinetic movement disorder with onset in infancy. American Journal of Human Genetics 98:4 (2016), 735–743.
66. Disbrow, E.A., Carmichael, O., He, J., Lanni, K.E., Dressler, E.M., Zhang, L., et al. Resting state functional connectivity is associated with cognitive dysfunction in non-demented people with Parkinson's disease. Journal of Parkinson's Disease 4 (2014), 453–465.
67. Doder, M., Rabiner, E.A., Turjanski, N., Lees, A.J., Brooks, D.J., Tremor in Parkinson's disease and serotonergic dysfunction: An 11C-WAY 100635 PET study. Neurology 60 (2003), 601–605.
68. Du, G., Lewis, M.M., Styner, M., Shaffer, M.L., Sen, S., Yang, Q.X., et al. Combined R2* and diffusion tensor imaging changes in the substantia nigra in Parkinson's disease. Movement Disorders 26 (2011), 1627–1632.
69. Edison, P., Ahmed, I., Fan, Z., Hinz, R., Gelosa, G., Ray Chaudhuri, K., et al. Microglia, amyloid, and glucose metabolism in Parkinson's disease with and without dementia. Neuropsychopharmacology 38:6 (2013), 938–949.
70. Edison, P., Rowe, C.C., Rinne, J.O., Ng, S., Ahmed, I., Kemppainen, N., et al. Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. Journal of Neurology, Neurosurgery, and Psychiatry 79 (2008), 1331–1338.
71. Ekelund, J., Slifstein, M., Narendran, R., Guillin, O., Belani, H., et al. In vivo DA D(1) receptor selectivity of NNC 112 and SCH 23390. Molecular Imaging and Biology 9:3 (2007), 117–125.
72. Evans, A.H., Pavese, N., Lawrence, A.D., Tai, F.Y., Appel, S., Doder, M., et al. Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Annals of Neurology 59 (2006), 852–858.
73. Fernandez-Seara, M.A., Mengual, E., Vidorreta, M., Castellanos, G., Irigoyen, J., Erro, E., et al. Resting state functional connectivity of the subthalamic nucleus in Parkinson's disease assessed using arterial spin-labeled perfusion fMRI. Human Brain Mapping 36 (2015), 1937–1950.
74. Foster, E.R., Campbell, M.C., Burack, M.A., Hartlein, J., Flores, H.P., Cairns, N.J., et al. Amyloid imaging of Lewy body-associated disorders. Movement Disorders 25 (2010), 2516–2523.
75. Fredholm, B.B., Svenningsson, P., Adenosine-dopamine interactions: Development of a concept and some comments on therapeutic possibilities. Neurology 61 (2003), S5–S9.
76. Fujishige, K., Kotera, J., Omori, K., Striatum- and testis-specific phosphodiesterase PDE10A isolation and characterization of a rat PDE10A. European Journal of Biochemistry 266 (1999), 1118–1127.
77. Fujita, M., Ichise, M., Zoghbi, S.S., Liow, J.S., Ghose, S., Vines, D.C., et al. Widespread decrease of nicotinic acetylcholine receptors in Parkinson's disease. Annals of Neurology 59 (2006), 174–177.
78. Fujita, M., Imaizumi, M., Zoghbi, S.S., Fujimura, Y., Farris, A.G., Suhara, T., et al. Kinetic analysis in healthy humans of a novel positron emission tomography radioligand to image the peripheral benzodiazepine receptor, a potential biomarker for inflammation. NeuroImage 40 (2008), 43–52.
79. Gerhard, A., Pavese, N., Hotton, G., Turkheimer, F., Es, M., Hammers, A., et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiology of Disease 21:2 (2006), 404–412.
80. Gilman, S., Koeppe, R.A., Nan, B., Wang, C.N., Wang, X., Junck, L., et al. Cerebral cortical and subcortical cholinergic deficits in parkinsonian syndromes. Neurology 74:18 (2010), 1416–1423.
81. Girault, J.A., Integrating neurotransmission in striatal medium spiny neurons. Advances in Experimental Medicine and Biology 970 (2012), 407–429.
82. Gjerløff, T., Fedorova, T., Knudsen, K., Munk, O.L., Nahimi, A., Jacobsen, S., et al. Imaging acetylcholinesterase density in peripheral organs in Parkinson's disease with 11C-donepezil PET. Brain 138:Pt. 3 (2015), 653–663.
83. Gjerloff, T., Jakobsen, S., Nahimi, A., Munk, O.L., Bender, D., Alstrup, A.K., et al. In vivo imaging of human acetylcholinesterase density in peripheral organs using 11C-donepezil: Dosimetry, biodistribution, and kinetic analyses. Journal of Nuclear Medicine 55 (2014), 1818–1824.
84. Glass, M., Dragunow, M., Faull, R.L.M., Cannabinoid receptors in the human brain: A detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 77 (1997), 299–318.
85. Gomperts, S.N., Locascio, J.J., Makaretz, S.J., Schultz, A., Caso, C., Vasdev, N., et al. Tau positron emission tomographic imaging in the Lewy body diseases. JAMA Neurology 73:11 (2016), 1334–1341.
86. Gomperts, S.N., Locascio, J.J., Marquie, M., Santarlasci, A.L., Rentz, D.M., Maye, J., et al. Brain amyloid and cognition in Lewy body diseases. Movement Disorders 27 (2012), 965–973.
87. Gomperts, S.N., Locascio, J.J., Rentz, D., Santarlasci, A., Marquie, M., Johnson, K.A., et al. Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia. Neurology 80 (2013), 85–91.
88. Gomperts, S.N., Rentz, D.M., Moran, E., Becker, J.A., Locascio, J.J., Klunk, W.E., et al. Imaging amyloid deposition in Lewy body diseases. Neurology 71 (2008), 903–910.
89. Gonzalez-Garcia, N., Armony, J.L., Soto, J., Trejo, D., Alegria, M.A., Drucker-Colin, R., Effects of rTMS on Parkinson's disease: A longitudinal fMRI study. Journal of Neurology 258 (2011), 1268–1280.
90. Gorges, M., Muller, H.P., Lule, D., Pinkhardt, E.H., Ludolph, A.C., Kassubek, J., To rise and to fall: Functional connectivity in cognitively normal and cognitively impaired patients with Parkinson's disease. Neurobiology of Aging 36 (2015), 1727–1735.
91. Graff-Radford, J., Boeve, B.F., Pedraza, O., Ferman, T.J., Przybelski, S., Lesnick, T.G., et al. Imaging and acetylcholinesterase inhibitor response in dementia with Lewy bodies. Brain 135 (2012), 2470–2477.
92. Haacke, E.M., Makki, M., Ge, Y., Maheshwari, M., Sehgal, V., Hu, J., et al. Characterizing iron deposition in multiple sclerosis lesions using susceptibility weighted imaging. Journal of Magnetic Resonance Imaging 29 (2009), 537–544.
93. Hacker, C.D., Perlmutter, J.S., Criswell, S.R., Ances, B.M., Snyder, A.Z., Resting state functional connectivity of the striatum in Parkinson's disease. Brain 135:Pt. 12 (2012), 3699–3711.
94. Halldin, C., Stone-Elander, S., Farde, L., Ehrin, E., Fasth, K.J., Langstrom, B., et al. Preparation of 11C-labelled SCH 23390 for the in vivo study of dopamine D-1 receptors using positron emission tomography. International Journal of Radiation Applications and Instrumentation. Part A 37:10 (1986), 1039–1043.
95. Hamani, C., Lozano, A.M., Physiology and pathophysiology of Parkinson's disease. Annals of the New York Academy of Sciences 991 (2003), 15–21.
96. Harding, A.J., Halliday, G.M., Cortical Lewy body pathology in the diagnosis of dementia. Acta Neuropathologica 102:4 (2001), 355–363.
97. Hawkes, C.H., Del Tredici, K., Braak, H., Parkinson's disease: A dual-hit hypothesis. Neuropathology and Applied Neurobiology 33:6 (2007), 599–614.
98. Hayashi, T., Su, T.P., Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2 +) signaling and cell survival. Cell 131 (2007), 596–610.
99. Helmich, R.C., Derikx, L.C., Bakker, M., Scheeringa, R., Bloem, B.R., Toni, I., Spatial remapping of cortico-striatal connectivity in Parkinson's disease. Cerebral Cortex 20:5 (2010), 1175–1186.
100. Helmich, R.C., Janssen, M.J., Oyen, W.J., Bloem, B.R., Toni, I., Pallidal dysfunction drives a cerebellothalamic circuit into Parkinson tremor. Annals of Neurology 69 (2011), 269–281.
101. Herkenham, M., Lynn, A.B., Johnson, M.R., Melvin, L.S., de Costa, B.R., Rice, K.C., Characterization and localization of cannabinoid receptors in the rat brain: A quantitative in vitro autoradiographic study. The Journal of Neuroscience 11 (1991), 563–583.
102. Herz, D.M., Eickhoff, S.B., Lokkegaard, A., Siebner, H.R., Functional neuroimaging of motor control in Parkinson's disease: A meta-analysis. Human Brain Mapping 35 (2014), 3227–3237.
103. Herz, D.M., Haagensen, B.N., Christensen, M.S., Madsen, K.H., Rowe, J.B., Lokkegaard, A., Abnormal dopaminergic modulation of striato-cortical networks underlies levodopa-induced dyskinesias in humans. Brain 138 (2015), 1658–1666.
104. Herz, D.M., Haagensen, B.N., Nielsen, S.H., Madsen, K.H., Lokkegaard, A., Siebner, H.R., Resting-state connectivity predicts levodopa-induced dyskinesias in Parkinson's disease. Movement Disorders 31 (2016), 521–529.
105. Hilker, R., Schweitzer, K., Coburger, S., Ghaemi, M., Weisenbach, S., Jacobs, A.H., et al. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Archives of Neurology 62 (2005), 378–382.
106. Hilker, R., Thomas, A.V., Klein, J.C., Weisenbach, S., Kalbe, E., Burghaus, L., et al. Dementia in Parkinson disease: Functional imaging of cholinergic and dopaminergic pathways. Neurology 65 (2005), 1716–1722.
107. Horvath, J., Herrmann, F.R., Burkhard, P.R., Bouras, C., Kövari, E., Neuropathology of dementia in a large cohort of patients with Parkinson's disease. Parkinsonism & Related Disorders 19:10 (2013), 864–868.
108. Hu, X., Song, X., Li, E., Liu, J., Yuan, Y., Liu, W., et al. Altered resting-state brain activity and connectivity in depressed Parkinson's disease. PLoS One, 10, 2015, e131133.
109. Huang, P., Lou, Y., Xuan, M., Gu, Q., Guan, X., Xu, X., et al. Cortical abnormalities in Parkinson's disease patients and relationship to depression: A surface-based morphometry study. Psychiatry Research 250 (2016), 24–28.
110. Iannaccone, S., Cerami, C., Alessio, M., Garibotto, V., Panzacchi, A., Olivieri, S., et al. In vivo microglia activation in very early dementia with Lewy bodies, comparison with Parkinson's disease. Parkinsonism & Related Disorders 19:1 (2013), 47–52.
111. Ibarretxe-Bilbao, N., Junque, C., Marti, M.J., Valldeoriola, F., Vendrell, P., Bargallo, N., Olfactory impairment in Parkinson's disease and white matter abnormalities in central olfactory areas: A voxel-based diffusion tensor imaging study. Movement Disorders 25 (2010), 1888–1894.
112. Ibarretxe-Bilbao, N., Junque, C., Segura BBaggio, H.C., Marti, M.J., Valldeoriola, F., et al. Progression of cortical thinning in early Parkinson's disease. Movement Disorders 27 (2012), 1746–1753.
113. Ikoma, Y., Yasuno, F., Ito, H., Suhara, T., Ota, M., Toyama, H., et al. Quantitative analysis for estimating binding potential of the peripheral benzodiazepine receptor with [(11)C]DAA1106. Journal of Cerebral Blood Flow and Metabolism 27 (2007), 173–184.
114. Isaias, I.U., Spiegel, J., Brumberg, J., Cosgrove, K.P., Marotta, G., Oishi, N., et al. Nicotinic acetylcholine receptor density in cognitively intact subjects at an early stage of Parkinson's disease. Frontiers in Aging Neuroscience, 6, 2014, 213.
115. Ito, M., Watanabe, H., Kawai, Y., Atsuta, N., Tanaka, F., Naganawa, S., Usefulness of combined fractional anisotropy and apparent diffusion coefficient values for detection of involvement in multiple system atrophy. Journal of Neurology, Neurosurgery, and Psychiatry 78 (2007), 722–728.
116. Iyo, M., Namba, H., Fukushi, K., Shinotoh, H., Nagatsuka, S., Suhara, T., et al. Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer's disease. Lancet 349 (1997), 1805–1809.
117. Jahanshahi, M., Jones, C.R.G., Zijlmans, J., Katsenschlager, R., Lee, L., Quinn, N., et al. Dopaminergic modulation of striato-frontal connectivityduring motor timing in Parkinson's disease. Brain 133 (2010), 727–745.
118. Jellinger, K.A., Pathology of Parkinson's disease. Molecular and Chemical Neuropathology 3 (1991), 153–197.
119. Jellinger, K.A., Attems, J., Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease. Acta Neuropathologica 115:4 (2008), 427–436.
120. Jellinger, K.A., Seppi, K., Wenning, G.K., Poewe, W., Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease. Journal of Neural Transmission (Vienna) 109:3 (2002), 329–339.
121. Johansson, A., Savitcheva, I., Forsberg, A., Engler, H., Långström, B., Nordberg, A., et al. [11C]-PIB imaging in patients with Parkinson's disease: Preliminary results. Parkinsonism & Related Disorders 14 (2008), 345–347.
122. Jokinen, P., Scheinin, N., Aalto, S., Någren, K., Savisto, N., Parkkola, R., et al. [11C]PIB-, [18F]FDG-PET and MRI imaging in patients with Parkinson's disease with and without dementia. Parkinsonism & Related Disorders 16 (2010), 666–670.
123. Jučaite, A., Cselényi, Z., Arvidsson, A., Ahlberg, G., Julin, P., Varnäs, K., et al. Kinetic analysis and test-retest variability of the radioligand [11C](R)-PK11195 binding to TSPO in the human brain—A PET study in control subjects. EJNMMI Research, 2, 2012, 15.
124. Jucaite, A., Svenningsson, P., Rinne, J.O., Cselényi, Z., Varnäs, K., Johnström, P., et al. Effect of the myeloperoxidase inhibitor AZD3241 on microglia: A PET study in Parkinson's disease. Brain 138:Pt 9 (2015), 2687–2700.
125. Junque, C., Ramírez-Ruiz, B., Tolosa, E., Summerfield, C., Martí, M.J., Pastor, P., et al. Amygdalar and hippocampal MRI volumetric reductions in Parkinson's disease with dementia. Movement Disorders 20 (2005), 540–544.
126. Kaasinen, V., Någren, K., Hietala, J., Oikonen, V., Vilkman, H., Farde, L., et al. Extrastriatal dopamine D2 and D3 receptors in early and advanced Parkinson's disease. Neurology 54:7 (2000), 1482–1487.
127. Kaasinen, V., Aalto, S., Nagren, K., Hietala, J., Sonninen, P., Rinne, J.O., Extrastriatal dopamine D(2) receptors in Parkinson's disease: A longitudinal study. Journal of Neural Transmission 110:6 (2003), 591–601.
128. Kahan, J., Urner, M., Moran, R., Flandin, G., Marreiros, A., Mancini, L., et al. Resting state functional MRI in Parkinson's disease: The impact of deep brain stimulation on ‘effective’ connectivity. Brain 137 (2014), 1130–1144.
129. Kantarci, K., Lowe, V.J., Boeve, B.F., Weigand, S.D., Senjem, M.L., Przybelski, S.A., et al. Multimodality imaging characteristics of dementia with Lewy bodies. Neurobiology of Aging 33 (2012), 2091–2105.
130. Kas, A., Bottlaender, M., Gallezot, J.D., Vidailhet, M., Villafane, G., Grégoire, M.C., et al. Decrease of nicotinic receptors in the nigrostriatal system in Parkinson's disease. Journal of Cerebral Blood Flow & Metabolism 29 (2009), 1601–1608.
131. Kashihara, K., Shinya, T., Higaki, F., Neuromelanin magnetic resonance imaging of nigral volume loss in patients with Parkinson's disease. Journal of Clinical Neuroscience 18:8 (2011), 1093–1096.
132. Kefalopoulou, Z., Politis, M., Piccini, P., Mencacci, N., Bhatia, K., Jahanshahi, M., et al. Long-term clinical outcome of fetal cell transplantation for Parkinson disease: Two case reports. JAMA Neurology 71 (2014), 83–87.
133. Klein, J.C., Eggers, C., Kalbe, E., Weisenbach, S., Hohmann, C., Vollmar, S., et al. Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo. Neurology 74 (2010), 885–892.
134. Ko, J.H., Mure, H., Tang, C.C., Ma, Y., Dhawan, V., Spetsieris, P., et al. Parkinson's disease: Increased motor network activity in the absence of movement. The Journal of Neuroscience 33 (2013), 4540–4549.
135. Koshimori, Y., Ko, J.H., Mizrahi, R., Rusjan, P., Mabrouk, R., Jacobs, M.F., et al. Imaging striatal microglial activation in patients with Parkinson's disease. PLoS One, 10(9), 2015, e0138721.
136. Kosta, P., Argyropoulou, M.I., Markoula, S., Konitsiotis, S., MRI evaluation of the basal ganglia size and iron content in patients with Parkinson's disease. Journal of Neurology 253 (2006), 26–32.
137. Kotagal, V., Albin, R.L., Müller, M.L., Koeppe, R.A., Chervin, R.D., Frey, K.A., et al. Symptoms of rapid eye movement sleep behavior disorder are associated with cholinergic denervation in Parkinson disease. Annals of Neurology 71:4 (2012), 560–568.
138. Kreutzberg, G.W., Microglia: A sensor for pathological events in the CNS. Trends in Neurosciences 19 (1996), 312–318.
139. Lakics, V., Karran, E.H., Boess, F.G., Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues. Neuropharmacology 59:6 (2010), 367–374.
140. Larsen, J.P., Beiske, A.G., Bekkelund, S.I., Dietrichs, E., Tysnes, O.B., Vilming, S.T., et al. Motor symptoms in Parkinson's disease. Tidsskrift for Den Norske Legeforening 128 (2008), 2068–2071.
141. Le Bihan, D., Looking into the functional architecture of the brain with diffusion MRI. Nature Reviews. Neuroscience 4 (2003), 469–480.
142. Lee, C.S., In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Annals of Neurology 47 (2000), 493–503.
143. Lewis, M.M., Du, G., Kidacki, M., Patel, N., Shaffer, M.L., Mailman, R.B., et al. Higher iron in the red nucleus marks Parkinson's dyskinesia. Neurobiology of Aging 34 (2013), 1497–1503.
144. Loane, C., Politis, M., Buspirone: What is it all about?. Brain Research 1461 (2012), 111–118.
145. Loane, C., Wu, K., Bain, P., Brooks, D.J., Piccini, P., Politis, M., Serotonergic loss in motorcircuitries correlates with severity of action-postural tremor in PD. Neurology 80 (2013), 1850–1855.
146. Loane, C., Wu, K., O'Sullivan, S.S., Lawrence, A.D., Woodhead, Z., Lees, A.J., et al. Psychogenic and neural visual-cue response in PD dopamine dysregulation syndrome. Parkinsonism & Related Disorders 21:11 (2015), 1336–1341.
147. Loberboym, M., Traves, T.A., Melamed, E., Lampl, Y., Hellman, M., Djaldetti, R., [I123]-EP/CIT SPECT imaging for distinguishing drug-induced Parkinsonism from Parkinson's disease. Movement Disorders 21:4 (2006), 510–514.
148. Lorenz, R., Samnick, S., Dillmann, U., Schiller, M., Ong, M.F., Faßbender, K., et al. Nicotinic α4β2 acetylcholine receptors and cognitive function in Parkinson's disease. Acta Neurologica Scandinavica 130:3 (2014), 164–171.
149. Luo, C., Chen, Q., Song, W., Chen, K., Guo, X., Yang, J., Resting-state fMRI study on drug-naive patients with Parkinson's disease and with depression. Journal of Neurology, Neurosurgery, and Psychiatry 85 (2014), 675–683.
150. Lyoo, C.H., Ryu, Y.H., Lee, M.S., Cerebral cortical areas in which thickness correlates with severity of motor deficits of Parkinson's disease. Journal of Neurology 258:10 (2011), 1871–1876.
151. MacDonald, P.A., MacDonald, A.A., Seergobin, K.N., Tamjeedi, R., Ganjavi, H., Provost, J.-S., et al. The effect of dopamine therapy on ventral and dorsal striatum-mediated cognition in Parkinson's disease: Support from functional MRI. Brain 134 (2011), 1447–1463.
152. Maeda, T., Nagata, K., Yoshida, Y., Kannari, K., Serotonergic hyperinnervation into the dopaminergic denervated striatum compensates for dopamine conversion from exogenously administered L-DOPA. Brain Research 1046 (2005), 230–233.
153. Maetzler, W., Liepelt, I., Reimold, M., Reischl, G., Solbach, C., Becker, C., et al. Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiology of Disease 34 (2009), 107–112.
154. Maetzler, W., Reimold, M., Liepelt, I., Solbach, C., Leyhe, T., Schweitzer, K., et al. [11C]PIB binding in Parkinson's disease dementia. NeuroImage 39 (2008), 1027–1033.
155. Mailleux, P., Vanderhaeghen, J.J., Localization of cannabinoid receptor in the human developing and adult basal ganglia. Higher levels in the striatonigral neurons. Neuroscience Letters 148 (1992), 173–176.
156. Mak, E., Bergsland, N., Dwyer, M.G., Zivadinov, R., Kandiah, N., Subcortical atrophy is associated with cognitive impairment in mild Parkinson disease: A combined investigation of volumetric changes, cortical thickness, and vertex-based shape analysis. AJNR. American Journal of Neuroradiology 35 (2014), 2257–2264.
157. Mak, E., Su, L., Williams, G.B., Firbank, M.J., Lawson, R.A., Yarnall, A.J., et al. Baseline and longitudinal grey matter changes in newly diagnosed Parkinson's disease: ICICLE-PD study. Brain 138:Pt. 10 (2015), 2974–2986.
158. Marek, K., Innis, R., van Dyck, C., Fussell, B., Early, M., Eberly, S., et al. [I123]β-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology 57:11 (2001), 2089–2094.
159. Martín, A.B., Fernandez-Espejo, E., Ferrer, B., Gorriti, M.A., Bilbao, A., Navarro, M., et al. Expression and function of CB1 receptor in the rat striatum: Localization and effects on D1 and D2 dopamine receptor-mediated motor behaviors. Neuropsychopharmacology 33 (2008), 1667–1679.
160. Martin-Bastida, A., Lao-Kaim, N.P., Loane, C., Politis, M., Roussakis, A.A., Valle-Guzman, N., et al. Motor associations of iron accumulation in deep grey matter nuclei in Parkinson's disease: A cross-sectional study of iron-related magnetic resonance imaging susceptibility. European Journal of Neurology 24 (2017), 357–365.
161. Matsui, H., Nishinaka, K., Oda, M., Niikawa, H., Kubori, T., Udaka, F., Dementia in Parkinson's disease: Diffusion tensor imaging. Acta Neurologica Scandinavica 116 (2007), 177–181.
162. Matsuura, K., Maeda, M., Yata, K., Ichiba, Y., Yamaguchi, T., Kanamaru, K., et al. Neuromelanin magnetic resonance imaging in Parkinson's disease and multiple system atrophy. European Neurology 70:1–2 (2013), 70–77.
163. Melzer, T.R., Watts, R., MacAskill, M.R., Pitcher, T.L., Livingston, L., Keenan, R.J., et al. Grey matter atrophy in cognitively impaired Parkinson's disease. Journal of Neurology, Neurosurgery, and Psychiatry 83 (2012), 188–194.
164. Mencacci, N.E., Kamsteeg, E.J., Nakashima, K., R'Bibo, L., Lynch, D.S., Balint, B., et al. De novo mutations in PDE10A cause childhood-onset chorea with bilateral striatal lesions. American Journal of Human Genetics 98:4 (2016), 763–771.
165. Meppelink, A.M., de Jong, B.M., Renken, R., Leenders, K.L., Cornelissen, F.W., van Laar, T., Impaired visual processing preceding image recognition in Parkinson's disease patients with visual hallucinations. Brain 132 (2009), 2980–2993.
166. Meyer, P.M., Strecker, K., Kendziorra, K., Becker, G., Hesse, S., Woelpl, D., et al. Reduced α4β2*–nicotinic acetylcholine receptor binding and its relationship to mild cognitive and depressive symptoms in Parkinson disease. Archives of General Psychiatry 66 (2009), 866–877.
167. Mishina, M., Ishiwata, K., Ishii, K., Kitamura, S., Kimura, Y., Kawamura, K., et al. Function of sigma1 receptors in Parkinson's disease. Acta Neurologica Scandinavica 112 (2005), 103–107.
168. Mishina, M., Ishiwata, K., Naganawa, M., Kimura, Y., Kitamura, S., Suzuki, M., et al. Adenosine A2A receptors measured with [11C]TMSX PET in the striata of Parkinson's disease patients. PLoS One, 6, 2011, e17338 1–8.
169. Müller, M.L., Frey, K.A., Petrou, M., Kotagal, V., Koeppe, R.A., Albin, R.L., et al. β-Amyloid and postural instability and gait difficulty in Parkinson's disease at risk for dementia. Movement Disorders 28:3 (2013), 296–301.
170. Mure, H., Tang, C.C., Argyelan, M., Ghilardi, M.-F., Kaplitt, M.G., Dhawan, V., et al. Improved sequence learning with subthalamic nucleus deep brain stimulation: Evidence for treatment-specific network modulation. The Journal of Neuroscience 32 (2012), 2804–2813.
171. Namba, H., Iyo, M., Shinotoh, H., Nagatsuka, S., Fukushi, K., Irie, T., Preserved acetylcholinesterase activity in aged cerebral cortex. Lancet 351 (1998), 881–882.
172. Nandhagopal, R., Kuramoto, L., Schulzer, M., Mak, E., Cragg, J., Lee, C.S., et al. Longitudinal progression of sporadic Parkinson's disease: A multi-tracer positron emission tomography study. Brain 132 (2009), 2970–2979.
173. Ng, K.Y., Chase, T.N., Kopin, I.J., Drug-induced release of 3H-norepinephrine and 3H-serotonin from brain slices. Nature 228:5270 (1970), 468–469.
174. Niccolini, F., Foltynie, T., Reis Marques, T., Muhlert, N., Tziortzi, A.C., Searle, G.E., et al. Loss of phosphodiesterase 10A expression is associated with progression and severity in Parkinson's disease. Brain 138:Pt. 10 (2015), 3003–3015.
175. Niccolini, F., Haider, S., Reis Marques, T., Muhlert, N., Tziortzi, A.C., Searle, G.E., et al. Altered PDE10A expression detectable early before symptomatic onset in Huntington's disease. Brain 138:Pt. 10 (2015), 3016–3029.
176. Nishi, A., Kuroiwa, M., Miller, D.B., O'Callaghan, J.P., Bateup, H.S., Shuto, T., et al. Distinct roles of PDE4 and PDE10A in the regulation of cAMP/PKA signaling in the striatum. The Journal of Neuroscience 28:42 (2008), 10460–10471.
177. Nurmi, E., Ruottinen, H.M., Bergman, J., Haaparanta, M., Solin, O., Sonninen, P., et al. Rate of progression in Parkinson's disease: A 6-[18F]fluoro-L-dopa PET study. Movement Disorders 16 (2001), 608–615.
178. Nurmi, E., Ruottinen, H.M., Kaasinen, V., Bergman, J., Haaparanta, M., Solin, O., et al. Progression in Parkinson's disease: A positron emission tomography study with a dopamine transporter ligand [18F]CFT. Annals of Neurology 47 (2000), 804–808.
179. O'Sullivan, S.S., Wu, K., Politis, M., Lawrence, A.D., Evans, A.H., Bose, S.K., et al. Cue induced striatal dopamine release in Parkinson's disease associated impulsive-compulsive behaviours. Brain 134:Pt. 4 (2011), 969–978.
180. Oh, U., Fujita, M., Ikonomidou, V.N., Evangelou, I.E., Matsuura, E., Harberts, E., et al. Translocator protein PET imaging for glial activation in multiple sclerosis. Journal of Neuroimmune Pharmacology 6 (2011), 354–361.
181. Ohtsuka, C., Sasaki, M., Konno, K., Koide, M., Kato, K., Takahashi, J., et al. Changes in substantia nigra and locus coeruleus in patients with early-stage Parkinson's disease using neuromelanin-sensitive MR imaging. Neuroscience Letters 541 (2013), 93–98.
182. Oishi, N., Hashikawa, K., Yoshida, H., Ishizu, K., Ueda, M., Kawashima, H., et al. Quantification of nicotinic acetylcholine receptors in Parkinson's disease with 123I-5IA SPECT. Journal of the Neurological Sciences 256 (2007), 52–60.
183. Olde Dubbelink, K.T., Schoonheim, M.M., Deijen, J.B., Twisk, J.W., Barkhof, F., Berendse, H.W., Functional connectivity and cognitive decline over 3 years in Parkinson disease. Neurology 83:22 (2014), 2046–2053.
184. Ouchi, Y., Kanno, T., Okada, H., Yoshikawa, E., Futatsubashi, M., Nobezawa, S., et al. Presynaptic and postsynaptic dopaminergic binding densities in the nigrostriatal and mesocortical systems in early Parkinson's disease: A double tracer positron emission tomography study. Annals of Neurology 46:5 (1999), 723–731.
185. Ouchi, Y., Yoshikawa, E., Sekine, Y., Futatsubashi, M., Kanno, T., Ogusu, T., et al. Microglial activation and dopamine terminal loss in early Parkinson's disease. Annals of Neurology 57:2 (2005), 168–175.
186. Owen, D.R., Guo, Q., Kalk, N.J., Colasanti, A., Kalogiannopoulou, D., Dimber, R., et al. Determination of [(11)C]PBR28 binding potential in vivo: A first human TSPO blocking study. Journal of Cerebral Blood Flow and Metabolism 34:6 (2014), 989–994.
187. Owen, D.R., Howell, O.W., Tang, S.P., Wells, L.A., Bennacef, I., Bergstrom, M., et al. Two binding sites for [3H]PBR28 in human brain: Implications for TSPO PET imaging of neuroinflammation. Journal of Cerebral Blood Flow and Metabolism 30 (2010), 1608–1618.
188. Owen, D.R., Yeo, A.J., Gunn, R.N., Song, K., Wadsworth, G., Lewis, A., et al. An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28. Journal of Cerebral Blood Flow and Metabolism 32 (2011), 1–5.
189. Pagano, G., Niccolini, F., Fusar-Poli, P., Politis, M., Serotonin transporter in Parkinson's disease: A meta-analysis of PET studies. Annals of Neurology 8 (2017), 171–180, 10.1002/ana.24859.
190. Pagano, G., Niccolini, F., Politis, M., Current status of PET imaging in Huntington's disease. European Journal of Nuclear Medicine and Molecular Imaging 43:6 (2016), 1171–1182.
191. Pagano, G., Niccolini, F., Politis, M., Imaging in Parkinson's disease. Clinical Medicine (London, England) 16:4 (2016), 371–375.
192. Pagonabarraga, J., Corcuera-Solano, I., Vives-Gilabert, Y., Llebaria, G., García-Sanchez, C., Pascual-Sedano, B., et al. Pattern of regional cortical thinning associated with cognitive deterioration in Parkinson's disease. PLoS One, 8, 2013, e54980.
193. Palmer, S.J., Li, J., Wang, Z.J., McKeown, M.J., Joint amplitude and connectivity compensatory mechanisms in Parkinson's disease. Neuroscience 166 (2010), 1110–1118.
194. Pavese, N., Evans, A.H., Tai, Y.F., Hotton, G., Brooks, D.J., Lees, A.J., et al. Clinical correlates of levodopa induced dopamine release in Parkinson's disease: A PET study. Neurology 67 (2006), 1612–1617.
195. Pavese, N., Metta, V., Bose, S.K., Chaudhuri, K.R., Brooks, D.J., Fatigue in Parkinson's disease is linked to striatal and limbic serotonergic dysfunction. Brain 133 (2010), 3434–3443.
196. Pavese, N., Rivero-Bosch, M., Lewis, S.J., Whone, A.L., Brooks, D.J., Progression of monoaminergic dysfunction in Parkinson's disease: A longitudinal 18F-dopa PET study. NeuroImage 56 (2011), 1463–1468.
197. Pellicano, C., Niccolini, F., Wu, K., O'Sullivan, S.S., Lawrence, A.D., Lees, A.J., et al. Morphometric changes in the reward system of Parkinson's disease patients with impulse control disorders. Journal of Neurology 262:12 (2015), 2653–2661.
198. Péran, P., Cherubini, A., Assogna, F., Piras, F., Quattrocchi, C., Peppe, A., et al. Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature. Brain 133:11 (2010), 3423–3433.
199. Pereira, J.B., Svenningsson, P., Weintraub, D., Brønnick, K., Lebedev, A., Westman, E., et al. Initial cognitive decline is associated with cortical thinning in early Parkinson disease. Neurology 82 (2014), 2017–2025.
200. Perry, E.K., Irving, D., Kerwin, J.M., McKeith, I.G., Thompson, P., Collerton, D., et al. Cholinergic transmitter and neurotrophic activities in Lewy body dementia: Similarity to Parkinson's and distinction from Alzheimer disease. Alzheimer Disease & Associated Disorders 7 (1993), 69–79.
201. Petit-Taboué, M.C., Baron, J.C., Barré, L., Travère, J.M., Speckel, D., Camsonne, R., et al. Brain kinetics and specific binding of [11C]PK 11195 to omega 3 sites in baboons: Positron emission tomography study. European Journal of Pharmacology 200 (1991), 347–351.
202. Petrou, M., Bohnen, N.I., Müller, M.L., Koeppe, R.A., Albin, R.L., Frey, K.A., Aβ-amyloid deposition in patients with Parkinson disease at risk for development of dementia. Neurology 79 (2012), 1161–1167.
203. Phelps, M.E., Positron emission tomography provides molecular imaging of biological processes. Proceedings of the National Academy of Sciences of the United States of America 97 (2000), 9226–9233.
204. Piccini, P., Brooks, D.J., Bjorklund, A., Gunn, R.N., Grasby, P.M., Rimoldi, O., et al. Dopamine release from nigral transplants visualised in vivo in a Parkinson's patient. Nature Neuroscience 2:12 (1999), 1047–1048.
205. Piccini, P., Pavese, N., Brooks, D.J., Endogenous dopamine release after pharmacological challenges in Parkinson's disease. Annals of Neurology 53:5 (2003), 647–653.
206. Piccini, P., Pavese, N., Hagell, P., Reiner, J., Bjorklund, A., Oertel, W.H., et al. Factors affecting the clinical outcome after neural transplantation in Parkinson's disease. Brain 128:12 (2005), 2977–2986.
207. Piccini, P., Weeks, R.A., Brooks, D.J., Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias. Annals of Neurology 42 (1997), 720–726.
208. Politis, M., Dyskinesias after neural transplantation in Parkinson's disease: What do we know and what is next?. BMC Medicine, 8, 2010, 80.
209. Politis, M., Optimizing functional imaging protocols for assessing the outcome of fetal cell transplantation in Parkinson's disease. BMC Medicine, 9, 2011, 50.
210. Politis, M., Neuroimaging in Parkinson disease: From research setting to clinical practice. Nature Reviews. Neurology 10 (2014), 708–722.
211. Politis, M., Loane, C., Wu, K., Brooks, D.J., Piccini, P., Serotonergic mediated body mass index changes in Parkinson's disease. Neurobiology of Disease 43 (2011), 609–615.
212. Politis, M., Loane, C., Wu, K., O'Sullivan, S.S., Woodhead, Z., Kiferle, L., et al. Neural response to visual sexual cues in dopamine treatment-linked hypersexuality in Parkinson's disease. Brain 136:Pt. 2 (2013), 400–411.
213. Politis, M., Niccolini, F., Serotonin in Parkinson's disease. Behavioural Brain Research 277 (2015), 136–145.
214. Politis, M., Oertel, W.H., Wu, K., Quinn, N.P., Pogarell, O., Brooks, D.J., et al. Graft-induced dyskinesias in Parkinson's disease: High striatal serotonin/dopamine transporter ratio. Movement Disorders 26 (2011), 1997–2003.
215. Politis, M., Piccini, P., In vivo imaging of the integration and function of nigral grafts in clinical trials. Progress in Brain Research 200 (2012), 199–220.
216. Politis, M., Piccini, P., Pavese, N., Koh, S.B., Brooks, D.J., Evidence of dopamine dysfunction in the hypothalamus of patients with Parkinson's disease: An in vivo 11C-raclopride PET study. Experimental Neurology 214 (2008), 112–116.
217. Politis, M., Wu, K., Loane, C., Brooks, D.J., Kiferle, L., Turkheimer, F.E., et al. Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients. The Journal of Clinical Investigation 124 (2014), 1340–1349.
218. Politis, M., Wu, K., Loane, C., Kiferle, L., Molloy, S., Brooks, D.J., et al. Staging of sero-tonergic dysfunction in Parkinson's disease: An in vivo 11C-DASB PET study. Neurobiology of Disease 40 (2010), 216–221.
219. Politis, M., Wu, K., Loane, C., Quinn, N.P., Brook, D.J., Oertel, W.H., et al. Serotonin neuron loss and non motor symptoms continue in Parkinson's patients treated with dopamine grafts. Science Translational Medicine 4 (2014), 128–141.
220. Politis, M., Wu, K., Loane, C., Quinn, N.P., Brooks, D.J., Rehncrona, S., et al. Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants. Science Translational Medicine 2 (2010), 38–46.
221. Politis, M., Wu, K., Loane, C., Turkheimer, F.E., Molloy, S., Brooks, D.J., et al. Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structures. Neurology 75 (2010), 1920–1927.
222. Quik, M., Bordia, T., Forno, L., McIntosh, J.M., Loss of alpha-conotoxinMII- and A85380-sensitive nicotinic receptors in Parkinson's disease striatum. Journal of Neurochemistry 88 (2004), 668–679.
223. Rabiner, E.A., Slifstein, M., Nobrega, J., Plisson, C., Huiban, M., Raymond, R., et al. In vivo quantification of regional dopamine-D3 receptor binding potential of [11C]PHNO: Studies in nonhuman primates and transgenic mice. Synapse 63:9 (2009), 782–793.
224. Ramírez-Ruiz, B., Martí, M.J., Tolosa, E., Giménez, M., Bargalló, N., Valldeoriola, F., et al. Cerebral atrophy in Parkinson's disease patients with visual hallucinations. European Journal of Neurology 14:7 (2007), 750–756.
225. Ramlackhansingh, A.F., Bose, S.K., Ahmed, I., Turkheimer, F.E., Pavese, N., Brooks, D.J., Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease. Neurology 76 (2011), 1811–1816.
226. Renaudo, A., L'Hoste, S., Guizouarn, H., Borgèse, F., Soriani, O., Cancer cell cycle modulated by a functional coupling between sigma-1 receptors and Cl- channels. The Journal of Biological Chemistry 282 (2007), 2259–2267.
227. Rinne, J.O., Laihinen, A., Nagren, K., Bergman, J., Haaparanta, M., Solin, O., et al. Positron emission tomography of brain dopamine D-1 receptors with 11C-SCH23390 in Parkinson's disease. Acta Radiologica. Supplementum, 376, 1991, 152.
228. Rinne, J.O., Laihinen, A., Rinne, U.K., Nagren, K., Bergman, J., Ruotsalainen, U., PET study on striatal dopamine D2 receptor changes during the progression of early Parkinson's disease. Movement Disorders 8:2 (1993), 134–138.
229. Rinne, J.O., Laihinen, A., Ruottinen, H., Ruotsalainen, U., Nagren, K., Lehikoinen, P., et al. Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease: A PET study with [11C]raclopride. Journal of the Neurological Sciences 132:2 (1995), 156–161.
230. Rinne, J.O., Myllykylä, T., Lönnberg, P., Marjamäki, P., A postmortem study of brain nicotinic receptors in Parkinson's and Alzheimer's disease. Brain Research 547:1 (1991), 167–170.
231. Roussakis, A.A., Piccini, P., Politis, M., Clinical utility of DaTscan™ (123I-ioflupane injection) in the diagnosis of parkinsonian syndromes. Degenerative Neurological and Neuromuscular Disease 3 (2013), 33–39.
232. Rowe, C.C., Ng, S., Ackermann, U., Gong, S.J., Pike, K., Savage, G., et al. Imaging β-amyloid burden in aging and dementia. Neurology 68 (2007), 1718–1725.
233. Russell, D.S., Barret, O., Jennings, D.L., Friedman, J.H., Tamagnan, G.D., Thomae, D., et al. The phosphodiesterase 10 positron emission tomography tracer, [18F]MNI-659, as a novel biomarker for early Huntington disease. JAMA Neurology 71:12 (2014), 1520–1528.
234. Russell, D.S., Jennings, D.L., Barret, O., Tamagnan, G.D., Carroll, V.M., Caillé, F., et al. Change in PDE10 across early Huntington disease assessed by [18F]MNI-659 and PET imaging. Neurology 86:8 (2016), 748–754.
235. Samadi, P., Bedard, P.J., Rouillard, C., Opioids and motor complications in Parkinson's disease. Trends in Pharmacological Sciences 27 (2006), 512–517.
236. Samii, A., Nutt, J.G., Ransom, B.R., Parkinson's disease. Lancet 363:9423 (2004), 1783–1793.
237. Sasaki, M., Shibata, E., Tohyama, K., Takahashi, J., Otsuka, K., Tsuchiya, K., et al. Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease. Neuroreport 17:11 (2006), 1215–1218.
238. Sawle, G.V., Playford, E.D., Brooks, D.J., Quinn, N., Frackowiak, R.S., Asymmetrical presynaptic and postsynaptic changes in the striatal dopamine projection in dopa naïve parkinsonism. Diagnostic implications of the D2 receptor status. Brain 116 (1993), 853–867.
239. Schliebs, R., Arendt, T., The cholinergic system in aging and neuronal degeneration. Behavioural Brain Research 221 (2011), 555–563.
240. Schmaljohann, J., Gündisch, D., Minnerop, M., Bucerius, J., Joe, A., Reinhardt, M., et al. In vitro evaluation of nicotinic acetylcholine receptors with 2-[18F]F-A85380 in Parkinson's disease. Nuclear Medicine and Biology 33:3 (2006), 305–309.
241. Schrag, A., Politis, M., Serotonergic loss underlying apathy in Parkinson's disease. Brain 139:Pt. 9 (2016), 2338–2339.
242. Schwarz, S.T., Afzal, M., Morgan, P.S., Bajaj, N., Gowland, P.A., Auer, D.P., The ‘swallow tail’ appearance of the healthy nigrosome—A new accurate test of Parkinson's disease: A case–control and retrospective cross-sectional MRI study at 3T. PLoS One, 9, 2014, e93814.
243. Schwarz, S.T., Rittman, T., Gontu, V., Morgan, P.S., Bajaj, N., Auer, D.P., T1-weighted MRI shows stage-dependent substantia nigra signal loss in Parkinson's disease. Movement Disorders 26:9 (2011), 1633–1638.
244. Schwarz, S.T., Xing, Y., Tomar, P., Bajaj, N., Auer, D.P., In vivo assessment of brainstem depigmentation in Parkinson disease: Potential as a severity marker for multicenter studies. Radiology, 7, 2016, 160662.
245. Segura, B., Baggio, H.C., Marti, M.J., Valldeoriola, F., Compta, Y., Garcia-Diaz, A.I., et al. Cortical thinning associated with mild cognitive impairment in Parkinson's disease. Movement Disorders 29 (2014), 1495–1503.
246. Seibert, T.M., Murphy, E.A., Kaestner, E.J., Brewer, J.B., Interregional correlations in Parkinson disease and Parkinson-related dementia with resting functional MR imaging. Radiology 263 (2012), 226–234.
247. Shimada, H., Hirano, S., Shinotoh, H., Aotsuka, A., Sato, K., Tanaka, N., et al. Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET. Neurology 73 (2009), 273–278.
248. Shimada, H., Shinotoh, H., Hirano, S., Miyoshi, M., Sato, K., Tanaka, N., et al. β-Amyloid in Lewy body disease is related to Alzheimer's disease-like atrophy. Movement Disorders 28:2 (2013), 169–175.
249. Shine, J.M., Halliday, G.M., Gilat, M., Matar, E., Bolitho, S.J., Carlos, M., et al. The role of dysfunctional attentional networks in visual misperceptionsin Parkinson's disease. Human Brain Mapping 35 (2014), 2206–2219.
250. Shine, J.M., Mata, E., Ward, P.B., Bolitho, S.J., Pearson, M., Naismith, S.L., et al. Differential neural activation patterns in patients with Parkinson's disease and freezing of gait in response to concurrent cognitive and motorload. PLoS One, 8(1), 2013, e52602.
251. Shiozaki, K., Iseki, E., Uchiyama, H., Watanabe, Y., Haga, T., Kameyama, K., et al. Alterations of muscarinic acetylcholine receptor subtypes in diffuse Lewy body disease: Relation to Alzheimer's disease. Journal of Neurology, Neurosurgery, and Psychiatry 67 (1999), 209–213.
252. Siderowf, A., Pontecorvo, M.J., Shill, H.A., Mintun, M.A., Arora, A., Joshi, A.D., et al. PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F-AV-133 (florbenazine) in patients with Alzheimer's disease and Lewy body disorders. BMC Neurology, 14, 2014, 79.
253. Slifstein, M., Kegeles, L.S., Gonzales, R., Frankle, W.G., Xu, X., et al. [11C]NNC 112 selectivity for dopamine D1 and serotonin 5-HT(2A) receptors: A PET study in healthy human subjects. Journal of Cerebral Blood Flow and Metabolism 27:10 (2007), 1733–1741.
254. Steeves, T.D.L., Miyasaki, J., Zurowski, M., Lang, A.E., Pellecchia, G., van Elmeren, T., et al. Increased striatal dopamine release in parkinsonian patients with pathological gambling: A 11C-raclopride PET study. Brain 132 (2009), 1376–1385.
255. Su, P., Politis, M., The role of microglia in neurodegenerative disease. Kaur, C., Eng-Ang, L., (eds.) Microglia: Biology, functions and roles in disease, 2012, Nova publishers, New York, 93–117.
256. Surdhar, I., Gee, M., Bouchard, T., Coupland, N., Malykhin, N., Camicioli, R., Intact limbic-prefrontal connections and reduced amygdala volumes in Parkinson's disease with mild depressive symptoms. Parkinsonism & Related Disorders 18 (2012), 809–813.
257. Tam, C.W.C., Burton, E.J., McKeith, I.G., Burn, D.J., O'Brien, J.T., Temporal lobe atrophy on MRI in Parkinson disease with dementia: A comparison with Alzheimer disease and dementia with Lewy bodies. Neurology 64 (2005), 861–865.
258. Tanaka, H., Kannari, K., Maeda, T., Tomiyama, M., Suda, T., Matsunaga, M., Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. Neuroreport 10 (1999), 631–634.
259. Tatsch, K., Schwarz, J., Mozley, P.D., Linke, R., Pogarell, O., Oertel, W.H., et al. Relationship between clinical features of Parkinson's disease and presynaptic dopamine transporter binding assessed with [I123]IPT and single-photon emission tomography. European Journal of Nuclear Medicine 24:4 (1997), 415–421.
260. Tedroff, J., Pederson, M., Aquilonius, S.M., Hartvig, P., Jacobsson, G., Langstrom, B., Levodopa induced changes in synaptic dopamine in patients with Parkinson's disease as measured by 11C-raclopride displacement and PET. Neurology 46 (1996), 1430–1436.
261. Tessitore, A., Esposito, F., Vitale, C., Santangelo, G., Amboni, M., Russo, A., et al. Default-mode network connectivity in cognitively unimpaired patients with Parkinson disease. Neurology 79:23 (2012), 2226–2232.
262. Tessitore, A., Santangelo, G., De Micco, R., Vitale, C., Giordano, A., Raimo, S., et al. Cortical thickness changes in patients with Parkinson's disease and impulse control disorders. Parkinsonism & Related Disorders 24 (2016), 119–125.
263. Turjanski, N., Lees, A.J., Brooks, D.J., In vivo studies on striatal dopamine D1 and D2 site binding in L-DOPA treated Parkinson's disease patients with and without dyskinesias. Neurology 49 (1997), 717–723.
264. Ulla, M., Bonny, J.M., Ouchchane, L., Rieu, I., Claise, B., Durif, F., Is R2* a new MRI biomarker for the progression of Parkinson's disease? A longitudinal follow-up. PLoS One, 8, 2013, e57904.
265. Vaillancourt, D.E., Spraker, M.B., Prodoehl, J., Abraham, I., Corcos, D.M., Zhou, X.J., et al. High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease. Neurology 72 (2009), 1378–1384.
266. van Laere, K., Casteels, C., Lunskens, S., Goffin, K., Grachev, I.D., Bormans, G., et al. Regional changes in type 1 cannabinoid receptor availability in Parkinson's disease in vivo. Neurobiology of Aging, 33, 2012, 620.
267. Van Nuenen, B.F.L., van Eimeren, T., van der Vegt, J.P.M., Buhmann, C., Klein, C., Bloem, B.R., et al. Mapping preclinical compensation in Parkinson's disease: An imaging genomics approach. Movement Disorders 24 (2009), S703–S710.
268. Vas, A., Shchukin, Y., Karrenbauer, V.D., Cselényi, Z., Kostulas, K., Hillert, J., et al. Functional neuroimaging in multiple sclerosis with radiolabelled glia markers: Preliminary comparative PET studies with [11C]vinpocetine and [11C]PK11195 in patients. Journal of the Neurological Sciences 264 (2008), 9–17.
269. Vercruysse, S., Leunissen, I., Vervoort, G., Vandenberghe, W., Swinnen, S., Nieuwboer, A., Microstructural changes in white matter associated with freezing of gait in Parkinson's disease. Movement Disorders 30 (2015), 567–576.
270. Villemagne, V.L., Ong, K., Mulligan, R.S., Holl, G., Pejoska, S., Jones, G., et al. Amyloid imaging with 18F-florbetaben in Alzheimer disease and other dementias. Journal of Nuclear Medicine 52 (2011), 1210–1217.
271. Vingerhoets, F.J.G., Schulzer, M., Calne, D.B., Snow, B.J., Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion?. Annals of Neurology 41 (1997), 58–64.
272. Wallis, L.I., Paley, M.N., Graham, J.M., Grünewald, R.A., Wignall, E.L., Joy, H.M., et al. MRI assessment of basal ganglia iron deposition in Parkinson's disease. Journal of Magnetic Resonance Imaging 28 (2008), 1061–1067.
273. Weintraub, D., Doshi, J., Koka, D., Davatzikos, C., Siderowf, A.D., Duda, J.E., et al. Neurodegeneration across stages of cognitive decline in Parkinson disease. Archives of Neurology 68 (2011), 1562–1568.
274. Weiss, P.H., Herzog, J., Pötter-Nerger, M., Falk, D., Herzog, H., Deuschl, G., et al. Subthalamic nucleus stimulation improves parkinsonian gait viabrainstem locomotor centers. Movement Disorders 30:8 (2015), 1121–1125.
275. Weng, Y.H., Yen, T.C., Chen, M.C., Kao, P.F., Tzen, K.Y., Chen, R.S., et al. Sensitivity and specificity of (99m)Tc-TRODAT-1 SPECT imaging in differentiating patients with idiopathic Parkinson's disease from healthy subjects. Journal of Nuclear Medicine 45:3 (2004), 393–401.
276. Wieler, M., Gee, M., Martin, W.R., Longitudinal midbrain changes in early Parkinson's disease: Iron content estimated from R2*/MRI. Parkinsonism & Related Disorders 21 (2015), 179–183.
277. Wilson, A.A., Ginovart, N., Schmidt, M., Meyer, J.H., Threlkeld, P.G., Houle, S., Novel radiotracers for imaging the serotonin transporter by positron emission tomography: Synthesis, radiosynthesis, and in vitro and ex vitro evaluation of 11C labelled 2-(phenylthio) araalkylamines. Journal of Medicinal Chemistry 43 (2000), 3103–3110.
278. Winogrodzka, A., Bergmans, P., Booij, J., van Royen, E.A., Janssen, A.G., Wolters, E.C., [123I]FP-CIT SPECT is a useful method to monitor the rate of dopaminergic degeneration in early-stage Parkinson's disease. Journal of Neural Transmission (Vienna) 108:8–9 (2001), 1011–1019.
279. Winogrodzka, A., Bergmans, P., Booij, J., van Royen, E.A., Stoof, J.C., Wolters, E.C., [I123]β-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson's disease. Journal of Neurology, Neurosurgery, and Psychiatry 74:3 (2003), 294–298.
280. Wu, T., Long, X., Wang, L., Hallett, M., Zang, Y., Li, K., et al. Functionalconnectivity of cortical motor areas in the resting state in Parkinson's disease. Human Brain Mapping 32 (2011), 1443–1457.
281. Wu, T., Wang, L., Hallett, M., Chen, Y., Li, K., Chan, P., Effective connectivityof brain networks during self-initiated movement in Parkinson's disease. NeuroImage 55 (2011), 204–215.
282. Yao, N., Pang, S., Cheung, C., Chang, R.S., Lau, K.K., Suckling, J., et al. Resting activity in visual and corticostriatal pathways in Parkinson's disease with hallucinations. Parkinsonism & Related Disorders 21 (2015), 131–137.
283. Yoshikawa, K., Nakata, Y., Yamada, K., Nakagawa, M., Early pathological changes in the parkinsonian brain demonstrated by diffusion tensor MRI. Journal of Neurology, Neurosurgery, and Psychiatry 75 (2004), 481–484.
284. Zarei, M., Ibarretxe-Bilbao, N., Compta, Y., Hough, M., Junque, C., Bargallo, N., et al. Cortical thinning is associated with disease stages and dementia in Parkinson's disease. Journal of Neurology, Neurosurgery, and Psychiatry 84 (2013), 875–881.
285. Zhan, W., Kang, G.A., Glass, G.A., Zhang, Y., Shirley, C., Millin, R., et al. Regional alterations of brain microstructure in Parkinson's disease using diffusion tensor imaging. Movement Disorders 27 (2012), 90–97.
286. Zhang, W., Sun, S.G., Jiang, Y.H., Qiao, X., Sun, X., Wu, Y., Determination of brain iron content in patients with Parkinson's disease using magnetic susceptibility imaging. Neuroscience Bulletin 25 (2009), 353–360.
287. Zhang, J., Zhang, Y., Wang, J., Cai, P., Luo, C., Qian, Z., et al. Characterizing iron deposition in Parkinson's disease using susceptibility-weighted imaging: An in vivo MR study. Brain Research 1330 (2010), 124–130.
288. Zheng, Z., Shemmassian, S., Wijekoon, C., Kim, W., Bookheimer, S.Y., Pouratian, N., DTI correlates of distinct cognitive impairments in Parkinson's disease. Human Brain Mapping 35 (2014), 1325–1333.
289. Zhou, F.M., Wilson, C.J., Dani, J.A., Cholinergic interneuron characteristics and nicotinic properties in the striatum. Journal of Neurobiology 53:4 (2002), 590–605.